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BINDING OF TOLBUTAMIDE TO GLYCATED HUMAN SERUM
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K.S. Joseph, Jeanethe Anguizola, and David S. Hage*
Chemistry Department, University of Nebraska, Lincoln, Lincoln, NE 68588-0304 (USA)
Abstract
The presence of elevated levels of glucose in blood during diabetes can lead to the non-enzymatic
glycation of serum proteins such as human serum albumin (HSA). This study examined the
changes that occur in binding of the sulfonylurea drug tolbutamide to HSA as the level of
glycation for this protein was increased. High-performance affinity chromatography was used in
this work along with columns containing various preparations of in vitro glycated HSA. It was
found in frontal analysis experiments that the binding of tolbutamide with all of the tested
preparations of glycated HSA could be described by a two-site model involving both strong and
weak affinity interactions. The association equilibrium constants (Ka) for tolbutamide at its high
affinity sites on glycated HSA were in the range of 0.8–1.2 × 105 M−1 and increased by 1.4-fold in
going from normal HSA to mildly glycated HSA. It was found through competition studies that
tolbutamide was binding at both Sudlow sites I and II on the glycated HSA, in agreement with
previous studies. The Ka for tolbutamide at Sudlow site II increased by 1.1 to 1.4-fold in going
from normal HSA to glycated HSA. At Sudlow site I, the Ka for tolbutamide increased by 1.2 to
1.3-fold in going from normal HSA to the glycated HSA samples. This information demonstrates
the effects that glycation can have on drug interactions on HSA and should provide a better
quantitative understanding of how the protein binding of tolbutamide in serum may be affected for
individuals with diabetes.
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1. Introduction
It has been estimated that approximately 151 million people worldwide suffer from diabetes
[1] and that 23.6 million children and adults have diabetes in the U.S. [2]. Diabetes is a
group of disorders that pertain to insulin deficiency, insulin ineffectiveness, or a
combination of the two, resulting in glucose intolerance or hypoglycemia [1]. Type I
diabetes (i.e., juvenile-onset diabetes) occurs when the immune system destroys the cells
that make insulin and control blood glucose levels. Type II diabetes (i.e., non-insulin
dependent diabetes) begins with insulin resistance and leads to an eventual decrease in
insulin production. Type I and II diabetes occur in 5–10% and 90–95% of patients with
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diabetes, respectively [2]. Diabetes can lead to complications such as cardiovascular disease,
nerve damage, renal failure, and blindness. However, with proper treatment many of these
complications can be delayed or prevented. Roughly 57% of people with diabetes take oral
medication alone to treat this disease and 13% take both insulin and oral medication for
treatment [2].
Sulfonylurea drugs are often used to treat type II diabetes, either alone or in combination
with other drugs [3]. Tolbutamide (see Figure 1) was the first drug in this class to be used to
treat diabetes and has remained an important agent for this use since its discovery in 1956
[3]. At therapeutic levels, tolbutamide is 90% protein-bound in the circulation. This binding
is of interest for tolbutamide and other first-generation sulfonylureas (e.g., chlorpropamide,
acetohexamide, and tolazamide) because these agents are thought to be more easily
displaced from their carrier proteins than their second-generation counterparts [4]. In
addition, even a small change in the free (non-protein bound) fraction of tolbutamide can
lead to severe hypoglycemia [5,6].
Human serum albumin (HSA) is the most abundant protein in human plasma [6–12] and is
the main carrier protein for tolbutamide in serum [4]. This protein has a serum concentration
of ~40 g/L and is known to have two major binding sites for drugs: Sudlow sites I and II
[13]. Sudlow site I, which is found in subdomain IIA of HSA, binds to bulky heterocyclic
compounds such as coumarins, sulfonamides, and salicylate [6,8,9,14–16]. Sudlow site II,
found in subdomain IIIA, binds to aromatic carboxylic acids and profens [6,8,9,15]. HSA is
able to bind and transport both endogenous solutes (e.g., unesterified fatty acids) as well as a
wide range of drugs [6]. This binding can have a large affect on the pharmacologic and
pharmacokinetic properties of a drug such as tolbutamide by affecting its metabolism,
excretion, and bioavailability [6,17].
One process that is believed to affect the binding of drugs to HSA is glycation. Glycation
refers to the modification of a protein by a process that begins with the reaction between a
reducing sugar and a free amine group on a protein [10,18]. This process can occur for HSA
and becomes more pronounced in diabetes when an elevated amount of glucose is present in
the bloodstream. While an average individual has 6–13% of HSA in a glycated form, a
person with diabetes may have 20–30% or more glycated HSA in the circulation [6,10,11].
It has recently been shown that some of the primary modification sites for glycated HSA are
at or near Sudlow sites I and II [11,18,19]. This information, in turn, has created interest in
how these modifications may affect the binding of drugs such as tolbutamide to HSA [20].
This study will use high-performance affinity chromatography (HPAC) to examine the
binding of tolbutamide to HSA with various levels of glycation. HPAC is a type of HPLC
that uses a biological ligand as the stationary phase. HPAC has been used for many years as
a selective separation and analysis technique for chemical isolation and analysis, but this
approach can also be used as a tool to study various biological interactions (e.g., see recent
review in Ref. [21]). This current study will use columns that contain immobilized glycated
HSA to examine the binding of tolbutamide with this protein under various experimental
conditions. Some benefits of using HPAC over more traditional methods for drug binding
studies (e.g., equilibrium dialysis or ultrafiltration) include the good precision and
reproducibility of HPAC plus its small sample requirements and ease of automation. The
ability to reuse the same protein preparation for many experiments is also an attractive
feature of HPAC, as well as its good correlation versus reference methods (e.g., as has been
shown in numerous studies for normal HSA; see review in Ref. [21,22]).
This current report will first use frontal analysis to determine how the association
equilibrium constants and binding capacities change for columns containing in vitro
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glycated HSA with increasing levels of glycation [21,22]. Zonal elution studies will then be
performed to specifically examine the binding of tolbutamide at Sudlow sites I and II of
HSA as the levels of glycation are increased [21,22]. The knowledge gained from these
studies should give a better description of how glycation changes the binding of tolbutamide
with HSA. This information, in turn, may lead to the development of more effective drug
treatment regimes based on personalized medicine for patients with diabetes.
2. Theory
2.1 Frontal Analysis
Frontal analysis (or frontal affinity chromatography) was used to determine the association
equilibrium constant(s), Ka, and moles of binding sites, mL, for tolbutamide with glycated
HSA. An example of this type of experiment is given in Figure 2(a). If a system has single-
site binding, Eqns. (1) and (2) in Table 1 can be used with frontal analysis data to provide
information on the binding of an applied drug to the immobilized protein [21,22]. In these
equations, mLapp is the apparent moles of drug required to reach the central position of the
breakthrough curve at a given concentration of the applied drug. According to Eqn. (1), a
plot of 1/mLapp vs. 1/[A] should give a linear relationship if the drug binds to only one type
of binding site on the protein. In addition, deviations from linearity at high drug
concentrations (i.e., low 1/[A] values) can be used to detect multi-site interactions between
the drug and protein [22].
Similar expressions to Eqns. (1)–(2) can be written for a drug-protein system with more than
one type of interaction site, as shown in Eqns. (3) and (4) for a two-site binding model
[21,22]. In these equations, Ka1 and Ka2 are the association equilibrium constants of the
applied analyte A at sites 1 and 2, and mL1 or mL2 are the binding capacities for A at these
sites. The term α1 represents the fraction of all binding regions that make up the high affinity
binding sites (i.e., α1 = mL1,tot/mLtot). The term β2 is the ratio of the association equilibrium
constants for the lower affinity site (Ka2) versus the highest affinity site, where β2 = Ka2/Ka1
and 0 < Ka2 < Ka1. According to Eqn. (3), a non-linear response for a plot of 1/mLapp vs.
[A] would be expected throughout a broad range of concentrations for a system with multi-
site binding. However, at low concentrations a linear response can still be observed. In this
case, Eqn. (3) approaches the linear form shown in Eqn. (5) that can be used to estimate the
association equilibrium constant for the highest affinity sites by using data obtained at low
analyte concentrations [23].
2.2 Zonal Elution
HPAC and the method of zonal elution were used to examine the binding of tolbutamide to
glycated HSA at specific binding sites (see Figure 2(b)). In this approach, the retention time
(tR) of injected probe A (i.e., R-warfarin or L-tryptophan in this study) is measured in the
presence of various mobile phase concentrations of competing agent I (e.g., tolbutamide)
and is used to calculate the retention factor (k) for the injected probe, where k = (tR–tM)/tM)
and tM is the elution time of a non-retained solute (e.g., sodium nitrate).
If the injected probe and competing agent have direct competition at a single type of site on
an immobilized protein, Eqn. (6) in Table 1 can be used to describe the relationship between
the measured retention factor for A and the concentration of I [21,22]. In this equation, KaI
and KaA are the association equilibrium constants for the competing agent and site-selective
probe, respectively, at their site of competition and VM is the void volume. A plot of 1/k vs.
[I] in this case should yield a linear response if A and I follow a model based on direct
competition at a single type of binding site. The best-fit line for such a system can then be
used to find the association equilibrium constant for I at the site of competition by dividing
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the slope by the intercept. If multi-site competition or allosteric effects are present, a non-
linear response would instead be observed [22].
3. Experimental
3.1 Reagents
The tolbutamide ( ≥ 99.9% pure), R-warfarin (≥ 97%), L-tryptophan (98%), HSA
(essentially fatty acid free, ≥ 96%), and commercial glycated HSA (Lot 058K6087) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). The Nucleosil Si-300 (7 micron
particle diameter, 300 Å pore size) was from Macherey-Nagel (Düren, Germany). Reagents
for the bicinchoninic acid (BCA) protein assay were from Pierce (Rockford, IL, USA). The
assay kit for fructosamine (used for measuring glycation levels) was from Diazyme
Laboratories (San Diego, CA, USA). All aqueous were made using water from a Nanopure
system (Barnstead, Dubuque, IA, USA) and filtered with a 0.20 μm GNWP nylon
membrane from Millipore (Billerica, MA, USA).
3.2 Apparatus
The HPLC system consisted of a Jasco DG-2080-53 three-solvent degasser (Tokyo, Japan),
two Jasco PU-2080 isocratic pumps, a Rheodyne Advantage PF six-port valve (Cotati, CA,
USA), a Jasco AS-2055 autosampler, a Jasco CO-2060 column oven, and a Jasco UV-2075
UV/Vis detector. The HPLC system hardware was controlled by EZChrom Elite software
v3.2.1 (Scientific Software, Pleasanton, CA, USA) via Jasco LC Net hardware. An in-house
version of Labview 5.1 software (National Instruments, Austin, TX, USA) was used to
analyze the frontal analysis curves while PeakFit 4.12 (Jandel Scientific Software, San
Rafael, CA, USA) was used to determine the central moments of peaks obtained from zonal
elution experiments. Linear regression was performed using Excel 2003 (Microsoft
Corporation, Redmond, WA, USA) and non-linear regression was performed using DataFit
(Oakdale Engineering, PA, USA).
3.3 Methods
3.3.1 Column and Sample Preparation—Diol silica was made using Nucleosil Si-300
silica, and HSA was immobilized to the diol silica by the Schiff base method, both
according to previously-published procedures [16]. Control supports were prepared in the
same manner but with no HSA being added during the immobilization step. Although both
the Schiff base immobilization method and glycation involve the use of free amine groups
on a protein, it has been found that these two processes mainly involve different residues on
HSA; it has also been shown that the prior glycation of HSA (e.g., under the same
conditions as used in this report) does not change the specific activities at Sudlow sites I and
II when using warfarin or L-tryptophan as probes for these sites [24].
A BCA assay was performed in triplicate to determine the protein content of each glycated
HSA support, using soluble glycated HSA as the standard and the control support as the
blank. This report used three batches of HSA for immobilization, with each batch containing
a different level of glycation. The first HSA sample was purchased from Sigma (referred to
here as “gHSA1”). The second and the third samples (i.e., “gHSA2” and “gHSA3”,
respectively) were made in vitro by incubating a 42 g/L HSA solution for one month in
sterile pH 7.4 phosphate buffer with 15 mM or 30 mM glucose at 37ºC (Note: Sodium azide
was also added to prevent bacterial growth during incubation). The protein was then
purified, lyophilized, and stored at −80 °C until further use, according to methods described
in Ref. [24]. An enzymatic fructosamine assay from Diazyme Laboratories was used to
determine the level of glycation for each sample, as described previously [24], with the
results being expressed as mol hexose/mol HSA.
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The glycated HSA supports were downward slurry-packed into separate 2.0 cm × 2.1 mm
I.D. columns at 3500 psi (24 MPa) using pH 7.4, 0.067 M potassium phosphate buffer as the
packing solution. The control supports for each gHSA sample were packed into separate
columns under the same conditions. These columns were stored at 4 °C in the packing
solution and used over a period of one year and fewer than 500 sample applications per
column. The routine washing of these columns with fresh portions of sterile phosphate
buffer during the binding studies made it unnecessary to include a preservative in this
buffer; this approach also helped maintain conditions that closely corresponded to those seen
in vivo in serum during the binding studies. Columns containing normal HSA that have been
used in this manner have been found in previous studies to retain good stability for drug-
protein binding studies under such conditions [25].
The tolbutamide, R-warfarin, and L-tryptophan solutions were all made in pH 7.4, 0.067 M
potassium phosphate buffer. This same buffer was used as the application and elution buffer
in the chromatographic studies. All mobile phases were filtered through a 0.2 μM nylon
filter and degassed for 10–15 min prior to use. A flow rate of 0.5 ml/min was used for both
the frontal analysis and zonal elution studies, with all experiments being carried out at 37°C.
This flow rate has been shown in previous studies to give reproducible retention factors and
binding capacities for drug binding studies conducted on similar columns containing normal
HSA [26,27].
3.3.2 Chromatographic Studies—In the frontal analysis studies, the column was first
equilibrated with pH 7.4, 0.067 M potassium phosphate buffer. A switch was then made
between the pH 7.4 buffer and a drug solution that was prepared in the same buffer. Once
the drug had saturated the column and produced a breakthrough curve, the pH 7.4 buffer was
again passed through the column to elute the retained drug. The drug solutions contained 1–
200 μM tolbutamide and the elution of tolbutamide was monitored at 250 nm. Although the
pKa of sulfonylurea drugs like tolbutamide range from 5.2–6.2, even the solutions
containing the highest concentration of tolbutamide in this study gave less than a 0.05
change in pH for the pH 7.4 buffer, and the pH of this solution was found to vary by less
than 0.05 units over the course of this study. The frontal analysis experiments were
performed in triplicate at each drug concentration. The breakthrough curves were analyzed
by using Labview 5.1 and the equal areas method [22]. A correction for non-specific binding
to the system was made by subtracting the results for the control column from the data
obtained for each glycated HSA column.
Zonal elution competition studies were performed in triplicate using R-warfarin as a probe
for Sudlow site I and L-tryptophan as a probe for Sudlow site II [13]. Tolbutamide
concentrations of 1–20 μM were placed in the mobile phase while 20 μL injections of 5 μM
R-warfarin or L-tryptophan were made. These sample concentrations have been shown to
provide linear elution conditions for similar HSA columns [14,28]. The elution of R-
warfarin and L-tryptophan was monitored at 308 or 280 nm, respectively. Injections
containing 20 μL of 20 μM sodium nitrate were made under the same conditions using only
the pH 7.4 buffer as the mobile phase. Sodium nitrate was used as a non-retained solute to
determine column void time, with the elution of sodium nitrate being monitored at 205 nm.
The resulting peaks were fit to an exponentially-modified Gaussian curve and analyzed
using PeakFit v4.12.
4. Results and Discussion
4.1 Preparation of Glycated HSA
Earlier reports examining the binding of tolbutamide with HSA and glycated HSA have
examined either changes in the binding capacities of these proteins or the differences in their
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apparent binding constants [5,20]. These same reports, however, did not consider how the
tolbutamide-HSA interactions might change with various levels of glycation for HSA. In
addition, these reports measured binding constants at lower temperatures than are present in
the body (e.g., 20°C for the fluorescence quenching assay in Ref. [5]) or used higher glucose
concentrations for HSA glycation than are found in the body during diabetes [20]. These
issues and limitations were overcome in this current investigation by carrying out all binding
studies at 37ºC and by using HSA samples that had undergone various known levels of
glycation and that were prepared under conditions similar to those found in serum during
diabetes.
The glycated HSA samples that were used in this study were the same as employed in recent
work examining the changes in the HSA interactions with warfarin and L-tryptophan during
glycation [24]. The first sample of glycated HSA (gHSA1) contained 1.31 (± 0.05) mol
hexose/mol HSA (Note: the value in parentheses represents ± 1 S.D. for the population of
results). This sample was used to represent mildly glycated HSA, as might be found during
pre-diabetes or early state diabetes. The second glycated HSA sample (gHSA2) had a
glycation level of 2.34 (± 0.13) mol hexose/mol HSA; this sample was made using a glucose
concentration and conditions typical of those seen in many diabetic patients [29]. The third
sample (gHSA3) had a glycation level of 3.35 (± 0.14) mol hexose/mol HSA, as might be
present in uncontrolled or advanced diabetes. After these various preparations of glycated
HSA had been immobilized, the resulting supports were determined to have protein contents
of 29 (± 4), 47 (± 8), and 40 (± 3) mg protein/g silica, respectively, or ~440–710 nmol HSA/
g silica. These protein contents were comparable to those noted in earlier work with normal
HSA and comparable supports prepared by the same methods [16].
4.2 Frontal Analysis Studies of Tolbutamide Binding to Glycated HSA
The method of frontal analysis was used to gather information about the overall binding of
tolbutamide to glycated HSA. The data that was obtained for each type of glycated HSA
column was first plotted using a double-reciprocal plot (see example in Figure 3). When
using this type of model and plot, each glycated HSA column gave deviations at high drug
concentrations (i.e., low values of 1/[Tolbutamide]) from the expected linear response for a
single-site binding model, as described by Eqn. (1). This result indicated that tolbutamide
was binding to more than one binding site on each type of glycated HSA. This behavior was
consistent with similar studies using normal HSA, which has also been found to have multi-
site interactions for tolbutamide [30].
Eqn. (5) was next used with the upper linear region of plots like those in Figure 3 to estimate
the association equilibrium constant at the high-affinity sites for tolbutamide, according to a
method from Ref. [23,24]. This fit was obtained using data at tolbutamide concentrations of
1–10 μM for each of the columns. The resulting Ka values were between 0.9 and 1.1 × 105
M−1 at 37°C and pH 7.4, with correlation coefficients of at least 0.999 (n = 5 or 6) being
noted for a linear fit to the given region of the double-reciprocal plots for all glycated HSA
columns. These results were similar but slightly higher than a value of 0.82 (± 0.04) × 105
M−1 that was obtained by the sample approach when examining the high affinity sites of
tolbutamide on normal HSA [30].
A two-site model was next employed to examine the binding of tolbutamide with the
glycated HSA columns (see Figure 4). This was accomplished by analyzing the frontal
analysis data through the use of Eqn. (4) and non-linear regression. A two-site model has
been shown in earlier work to give the best fit for frontal analysis data acquired for
tolbutamide with normal HSA [30]. This model was also found in this current report to give
a good fit for the results obtained with tolbutamide on each glycated HSA column, giving
correlation coefficients of at least 0.999 (n = 9 to 11). Only random variations in the data
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about the best-fit lines were observed in these plots, along with a small sum of the square of
the residuals (range, 0.8 × 10−19 to 3.8 × 10−19). This overall fit gave much better agreement
with the data than a single-site model, which instead exhibited non-random variations of the
residuals about the best-fit lines along with correlation coefficients that ranged from 0.965–
0.998, and larger values for the sum of the square of the residuals (range, 4.3 × 10−18 to 7.4
× 10−18).
A summary is provided in Table 2 of the association equilibrium constants and amount of
each class of binding sites that were noted when using the two-site model for tolbutamide on
the glycated HSA columns. In this table, the association equilibrium constants found for the
high affinity regions (Ka1) were in good general agreement with the values of 0.9–1.1 × 105
M−1 that were estimated from the linear regions of plots prepared according to Eqn. (5), as
described previously in this section. When these results were compared to data that were
obtained by the same approach for tolbutamide on a normal HSA column (see entry from
Ref. [30] for normal HSA in Table 2), a 1.4-fold increase in affinity was present in going
from normal HSA (Ka1 = 0.87 (± 0.06) × 105 M−1) to the gHSA1 sample (Ka1 = 1.2 (± 0.2)
× 105 M−1), a change which was significant at the 95% confidence level. The apparent
association equilibrium constant for the high affinity regions returned to comparable values
versus normal HSA when using the gHSA2 and gHSA3 samples, which had Ka1 values of
0.84 (± 0.16) × 105 M−1 and 0.89 (± 0.06) × 105 M−1, respectively. The corresponding mL1
values for these high-affinity regions were 1.1–2.2 × 10−8 mol and corresponded to specific
activities of approximately 0.82–1.0 for all of these high affinity regions, with no apparent
change in these values as the level of glycation was varied.
The association equilibrium constants calculated for the lower affinity sites were comparable
to those obtained for tolbutamide when using similar affinity columns containing normal
HSA (for the latter value, see entry for normal HSA in Table 2 from Ref. [30]). The strength
of these weak affinity interactions was similar for normal HSA (Ka2 = 8.1 (± 1.7) × 103
M−1) [30] versus gHSA1 or gHSA2, in which these last two samples gave Ka2 values of 9.5
(± 3.2) × 103 M−1 and 7.8 (± 5.1) × 103 M−1, respectively. However, there was an apparent
decrease in Ka2 in going from normal HSA to gHSA3, in which this last sample had a Ka2
value of 1.7 (± 1.1) × 103 M−1. The corresponding specific activities for tolbutamide at these
low affinity sites ranged from 0.87 to 1.9 for the various glycated samples, which were
comparable to a value of 1.0 (± 0.1) that has been noted for tolbutamide with similar
columns containing normal HSA [30].
4.3 Site-Specific Interactions of Tolbutamide at Sudlow Site II
Zonal elution competition studies were used to further examine the interactions of
tolbutamide with glycated HSA. L-Tryptophan was first used in such work as a site-
selective probe to examine the binding of tolbutamide at Sudlow site II [30]. When the data
from these experiments were plotted according to Eqn. (6), a linear fit for all the glycated
HSA columns was observed (see example of such a plot in Figure 5). Similar linear behavior
and correlation coefficients between 0.998 and 0.999 (n = 5) were obtained for each
glycated HSA column examined in this study. In each case, only random residuals were
noted about the best-fit line. Based on this fit, it was determined that tolbutamide and L-
tryptophan had direct competition at a single site. In addition, it was possible to determine
that this competition was taking place at Sudlow site II because L-tryptophan is known to
bind selectively at this site on both normal HSA and the types of glycated HSA that were
examined in this study [24,28]. This result agrees with previous competition studies in
which tolbutamide has been found to be displaced by probes for Sudlow site II from both
normal HSA and glycated HSA [30].
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By using the best-fit lines from these plots and Eqn. (6), it was possible to find the
association equilibrium constant for tolbutamide at Sudlow site II by taking the ratio of the
slope to the intercept for each plot. This method has been used in a previous study with
normal HSA to obtain a site-specific association equilibrium constant of 5.3 (± 0.2) × 104
M−1 for tolbutamide at Sudlow site II [30]. The association equilibrium constants values that
were obtained at the same site in this study are summarized in Table 3. In going from
normal HSA to the mild level of glycation that was present in gHSA1, the size of Ka for
tolbutamide at Sudlow site II was found to increase by 1.1-fold to 5.9 (± 0.3) × 104 M−1
(i.e., an increase that was significant at the 90% confidence level). This was followed by
higher values of 7.2 (± 0.3) × 104 M−1 for the gHSA2 sample and 6.4 (± 0.3) × 104 M−1 for
the gHSA3 sample, or 1.4- to 1.2-fold increases versus normal HSA that were significant at
the 95% confidence level. It was also possible from the intercepts of these plots to determine
how the specific activity for tolbutamide at Sudlow site II was affected as the level of
glycation for HSA was increased. When this was done, no significant change in specific
activity was seen at the 95% confidence level for tolbutamide at Sudlow site II in going
from normal HSA to any of the glycated HSA columns.
4.4 Site-Specific Interactions of Tolbutamide at Sudlow Site I
Site-specific studies where also carried out using competition studies and R-warfarin as a
site-specific probe for Sudlow site I [14,16]. These results were again plotted according to
Eqn. (6), with an example being given in Figure 6. All of the glycated HSA columns gave
linear behavior for this type of plot, with correlation coefficients that ranged from 0.994 to
0.999 (n = 5) and with only random variations in the residuals being observed about the
best-fit line. This type of behavior indicated that tolbutamide and R-warfarin were
competing directly at Sudlow site I on HSA. Similar results have been noted in prior
competition studies for tolbutamide with probes for Sudlow site I when using both normal
HSA and glycated HSA [30].
The association equilibrium constant for tolbutamide at Sudlow site I on each of the
glycated HSA samples was found by using the best-fit lines of plots prepared according to
Eqn. (6). The results are summarized in Table 3. The Ka value for tolbutamide at Sudlow
site I on the gHSA1 column was roughly 1.3-fold higher than the value of 5.5 (± 0.2) × 104
M−1 that has previously been measured for tolbutamide at this site on normal HSA [30]. A
comparable, roughly 1.2-fold increase in affinity versus normal HSA was measured at the
same site for the gHSA2 and gHSA3 samples. All of the association equilibrium constants
measured at Sudlow site I for tolbutamide with the glycated HSA samples where
significantly different at the 95% confidence level when compared to the Ka value reported
for tolbutamide at the same site on normal HSA. No significant change at 95% confidence
level was seen in the specific activity for tolbutamide at Sudlow site I in going from normal
HSA to the glycated HSA columns.
5. Conclusion
This report looked at how the binding of tolbutamide with HSA changes as the level of
glycation for HSA is increased. Experiments based on the use of HPAC and frontal analysis
indicated that the binding of tolbutamide with glycated HSA followed a two-site model that
included a group of high affinity sites and a set of lower affinity interactions. This behavior
was in agreement with a previous report that has studied the binding of tolbutamide with
normal HSA [30]. The association equilibrium constants for the high affinity interactions
were in the general range of 0.8–1.2 × 105 M−1 and increased by 1.4-fold in going from
normal HSA to mildly glycated HSA (i.e., the gHSA1 sample), with the overall affinity
returning to more normal levels at higher levels of glycation (as noted for the gHSA2 and
gHSA3 samples). Competition studies based on zonal elution experiments found that the
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association equilibrium constant of tolbutamide at Sudlow site I increased by 1.2 to 1.3-fold
in going from normal HSA to all of the tested samples of glycated HSA. At Sudlow site II,
the association equilibrium constant for tolbutamide increased by 1.1- to 1.4-fold in going
from normal HSA to all of the tested samples of glycated HSA. Such an increase in binding
affinity to HSA upon glycation could potentially lower the amount of non-bound drug that is
available for binding to receptors and may affect the rate of metabolism or extraction and the
overall half-life of tolbutamide in the circulation.
As demonstrated in this report, the binding data that can be obtained through this type of
research can result in a better understanding of how glycation may change the interactions of
drugs such as tolbutamide to HSA during diabetes. This information should aid in the future
development of better patient treatments for personalized medicine by allowing physicians
to better understand how glycation may affect the activity of such a drug in the circulation
and to make appropriate adjustments in the prescribed dose when using tolbutamide and
related drugs. Similar binding studies are now being carried out with in vivo glycated HSA.
Work with additional pharmaceutical agents, including other sulfonylurea compounds, is
also in progress to determine the extent to which the interactions of these drugs may vary
during glycation of HSA.
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Figure 1.
Structure of tolbutamide.
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Figure 2.
(a) Frontal analysis and (b) zonal elution studies for tolbutamide on the gHSA1 column. The
tolbutamide concentrations in (a) were (top-to-bottom) 200, 100, 50, 20, and 10 μM. The
results in (b) were obtained using R-warfarin as a probe for Sudlow site II, along with
tolbutamide concentrations in the mobile phase (top-to-bottom) of 20, 15, 10, 5, and 1 μM.
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Figure 3.
Double-reciprocal plot of frontal analysis data obtained for tolbutamide on the gHSA1
column. The best-fit line for the upper linear region when analyzed according to Eqn. (5) is
y = 670 (± 20) x + [6.1 (± 1.0) × 107], r = 0.999, n = 6. The error bars represent a range of ±
1 SD and are of a comparable size to the data markers in this plot.
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Figure 4.
Plot of mLapp versus [Tolbutamide] for the gHSA1 column, as analyzed according to Eqn.
(4) and a two-site model. The best-fit values obtained for the association equilibrium
constants and binding capacities are summarized in Table 2. The data used in this plot was
the same as in Figure 3. The error bars for the data points (not shown) are comparable in size
to the data markers in this plot.
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Figure 5.
Zonal elution studies on the gHSA1 column for the injection of L-tryptophan as a site-
selective probe for Sudlow site II in the presence of tolbutamide as a competing agent. The
best-fit line obtained when using Eqn. (6) is y = [1.2 (± 0.1) × 104] x + 0.20 (± 0.01), r =
0.998, n = 5. The error bars represent a range ± 1 SD and are comparable in size to the data
markers in this plot.
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Figure 6.
Zonal elution studies on the gHSA1 column for the injection of R-warfarin as a site-selective
probe for Sudlow site I in the presence of tolbutamide as a competing agent. The best-fit line
obtained when using Eqn. (6) is y = 1500 (± 100) x + 0.021 (± 0.001), r = 0.999, n = 5. The
error bars represent a range of ± 1 SD and are comparable in size to the data markers in this
plot.
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Table 1
Equations used in frontal analysis and zonal elution experiments to obtain binding parameters for a drug with
an immobilized protein such as HSAa
Frontal Analysis
Single-site binding
1
mLapp
= 1(KamL A )
+ 1mL
(1)
mLapp =
mL Ka A
(1 + Ka A )
(2)
Two-site binding
1
mLapp
=
1 + Ka1 A + β2Ka1 A + β2Ka12 A 2
mLtot {(α1 + β2 − α1β2)Ka1 A + β2Ka12 A 2}
(3)
mLapp =
mL 1Ka1 A
(1 + Ka1 A )
+
mL 2Ka2 A
(1 + Ka2 A )
(4)
lim
A→0
1
mLapp
= 1mLtot (α1 + β2 − α1β2)Ka1 A
+
α1 + β22 − α1β22
mLtot (α1 + β2 − α1β2)2
(5)
Zonal Elution
Single-site competition
1
k =
KaIVM I
KaAmL
+
VM
KαAmL
(6)
a
A more detailed discussion of these equations and their use can be found in Refs. [21,22]. The terms used in these equations are defined in the
text.
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Table 3
Association equilibrium constants measured for tolbutamide at Sudlow sites I and II at pH 7.4 and 37°Ca
Tolbutamide Sudlow Site I (R-warfarin) (× 104 M−1) Sudlow Site II (L-tryptophan) (× 104 M−1)
Normal HSAb 5.5 (± 0.2) 5.3 (± 0.2)
gHSA1 6.9 (± 0.2) 5.9 (± 0.3)
gHSA2 6.6 (± 0.5) 7.2 (± 0.3)
gHSA3 6.5 (± 0.2) 6.4 (± 0.3)
a
The values in parenthesis represent a range of ± 1 S.D for the population of results. These values were determined by using error propagation and
the standard deviations of the slopes and intercepts that were obtained from best-fit lines generated according to Eqn. (6).
b
The results provided for normal HSA are based on previous work described in Ref. [30] and were acquired using experimental conditions
identical to those used in this current report for glycated HSA.
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